Astrazeneca

FromAstraZeneca ([email protected])
Subject (50)Enhertu efficacy results in HER2-low breast cancer
Preheader (150)Enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive a
Typography
Arial
Colors
Text Analysis
Body Words200
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px872 px
X-Spam Score-5.2
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeOvernight

Enhertu efficacy results in HER2-low breast cancer

Enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive a
Enhertu efficacy results in HER2-low breast cancer